Introduction to the South African Rheumatism and Arthritis Association 2024 guidelines
DOI:
https://doi.org/10.7196/Keywords:
rheumatoid arthriotis, perippheral spondyloarthritis, axial spondyloarthritis, biologic and targeted therapeis, South AfricaAbstract
The guidelines in this series provide evidence-based practical guidance for the diagnosis, treatment and follow-up of persons with inflammatory joint diseases. The purpose of these guidelines is to aid in shared decision-making between patient and physician, aiming to support high-quality clinical care. These guidelines have been prepared using the AGREE II instrument and based on adoption and, where appropriate, adaptation of international guidelines.
References
HodkinsonB,vanDuurenE,PettipherC,KallaA;SouthAfricanRheumatismandArthritisAssociation. South African recommendations for the management of rheumatoid arthritis: An algorithm for the standard of care in 2013. S Afr Med J 2013;103(8):576-585. https://doi.org/10.7196/SAMJ.7047
AGREE Next Steps Consortium (2017). The AGREE II Instrument (Electronic version). http://www. agreetrust.org (accessed 22 May 2018).
SmolenJS,LandewéRB,BijlsmaJW,etal.EULARrecommendationsforthemanagementofrheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79(6):685-699. https://doi.org/10.1136/annrheumdis-2019-216655
Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76(6):960-977. https://doi.org/10.1136/annrheumdis-2016-210715
Bech B, Primdahl J, van Tubergen A, et al. 2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. Ann Rheum Dis 2020;79(1):61-68. https://doi.org/10.1136/annrheumdis-2019-215458
Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79(6):700-712. https://doi.org/10.1136/annrheumdis-2020-217159
Coates L, Gossec L. The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: Similarities and differences. Joint Bone Spine 2023;90(1):105469. https://doi. org/10.1016/j.jbspin.2022.105469
Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 2023;82(1):19-34. https://doi.org/10.1136/ard- 2022-223296
Van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76(6):978-991. https://doi. org/10.1136/annrheumdis-2016-210770
Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2021;73(7):924-939. https://doi. org/10.1002/acr.24596
Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68(1):1-26. https://doi. org/10.1002/acr.22783
Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021. Nature Rev Rheumatol 2022;18(8):465-479. https://doi.org/10.1038/s41584-022-00798-0
Coates LC, FitzGerald O, Merola JF, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology consensus‐based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol 2018;70(3):345-355. https://doi.org/10.1002/art.40391
Smolen JS, Landewé RB, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023;82(1):3-18. https://doi.org/10.1136/ard-2022-223356
Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis 2024;83(6):706-719. https://doi.org/10.1136/ard-2024-225531
Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/ Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken) 2019;71(10):1599-1613. https://doi.org/10.1002/ acr.24025
Hamilton L, Barkham N, Bhalla A, et al. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. Rheumatology (Oxford) 2017;56(2):313-316. https://doi.org/10.1093/rheumatology/kew223
Tucker L, Allen A, Chandler D, et al. The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology (Oxford) 2022;61(9):e255-e266. https://doi.org/10.1093/rheumatology/keac295
Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. J Psoriasis Psoriatic Arthritis 2019;4(1):31-58. https://doi.org/10.1177/2475530318812244
Downloads
Published
Issue
Section
License
Copyright (c) 2024 B Hodkinson, E van Vuuren, A Maharaj, F Paruk, K Makan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
